SLC22A2 and Nephropathy: RAS inhibitors by competitive inhibition of OATP1B1 or 1B3 increase CDDP-in contact with its transporter to the kidneys, and Ang II is enough effective in stimulating and increasing the activity of the OCT2, and both eventually increase kidney damage.